Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002100119-26-001406
Filing Date
2026-07-31
Accepted
2026-07-31 10:20:21
Documents
1
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5747
  Complete submission text file 0002100119-26-001406.txt   7793
Mailing Address 660 W. GERMANTOWN PIKE SUITE 110 PLYMOUTH MEETING PA 19462
Business Address 660 W. GERMANTOWN PIKE SUITE 110 PLYMOUTH MEETING PA 19462 8584103134
INOVIO PHARMACEUTICALS, INC. (Subject) CIK: 0001055726 (see all company filings)

EIN.: 330969592 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-60487 | Film No.: 261226034
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 100 VANGUARD BLVD MALVERN PA 19355
Business Address 100 VANGUARD BLVD MALVERN PA 19355 610-669-6148
VANGUARD CAPITAL MANAGEMENT LLC (Filed by) CIK: 0002100119 (see all company filings)

EIN.: 392877419 | State of Incorp.: PA | Fiscal Year End: 1231
LEI: 529900ZEWTRLEJ6XE960
Type: SCHEDULE 13G